The Dictatorship
Trump administration touts lower prices for 15 Medicare drugs
NEW YORK (AP) — Pharmaceutical companies have agreed to slash the Medicare prices for 15 prescription drugs after months of negotiations, reductions that are expected to produce billions in savings for taxpayers and older adults, the Trump administration said.
But the net prices it unveiled for a 30-day supply of each drug are not what Medicare recipients will pay at their pharmacy counters, since those final amounts will depend on each individual’s plan and how much they spend on prescriptions in a given year.
Health Secretary Robert F. Kennedy Jr. touted the deals as part of the administration’s efforts to address affordability concerns among Americans. The Medicare drug negotiation program that made them possible is mandated by law and began under President Joe Biden’s administration.
“President Trump directed us to stop at nothing to lower health care costs for the American people,” Kennedy said in a statement Tuesday evening. “As we work to Make America Healthy Again, we will use every tool at our disposal to deliver affordable health care to seniors.”
The announcement marks the completion of a second round of negotiations under a 2022 law that allows Medicare to haggle over the price it pays on the most popular and expensive prescription drugs used by older Americans, bringing the total number of negotiated drug prices to 25. The new round of negotiated prices will go into effect in 2027. Reduced prices for the inaugural round of 10 drugs negotiated by the Biden administration last year will go into effect in January.
Price negotiations apply to drugs treating diabetes, asthma, cancers and more
The latest negotiated prices apply to some of the prescription medications on which Medicare spends the most money, including the massively popular GLP-1 weight-loss and diabetes drugs Ozempic, Rybelsus and Wegovy. Some of the other drugs involved in the negotiations include Trelegy Ellipta, which treats asthma; Otezla, a psoriatic arthritis drug; and various drugs that treat diabetes, irritable bowel syndrome and different forms of cancer.
Dr. Mehmet Oz, Centers for Medicare and Medicaid Services administrator, said the administration delivered “substantially better outcomes for taxpayers and seniors in the Medicare Part D program” than the previous year’s deals.
Under the first round of Medicare price negotiations, the Biden administration said the program would have saved about $6 billion on net covered prescription drug costs, or about 22%, if it had been in effect the previous year. The Trump administration said its latest round would have saved the government about $8.5 billion in net spending, or 36%, if it had been in effect last year.
It’s unclear exactly how much money the newly announced deals could save Medicare beneficiaries when they are buying prescription drugs at the pharmacy because those costs are determined by various individual factors.
A new rule that kicked off this year also caps out-of-pocket drug costs for Medicare beneficiaries at $2,000, giving some relief to older adults affected by high-cost prescriptions. The administration said estimated out-of-pocket savings for Medicare beneficiaries with drug plans is about $685 million.
Spencer Perlman, director of health care research at Veda Partners, said the Trump administration’s improved outcomes probably resulted from the mix of drugs being negotiated and lessons learned from the first year of negotiations.
Net drug prices are proprietary, he said, but “if we take the administration at their word, I think it demonstrates that they have secured meaningful price concessions for seniors, meaning the Medicare Drug Price Negotiation Program is working as intended.”
Medicare recipients can’t get GLP-1 drugs for obesity, but the administration is making changes
The GLP-1 weight-loss drugs that were part of the negotiations have been especially scrutinized for their high out-of-pocket costs. Yet it’s still unclear to what extent Medicare beneficiaries who want to use the drugs to treat obesity will be able to do so.
Medicare has long been prohibited from paying for weight-loss treatments, but a separate deal recently announced between the Trump administration and two pharmaceutical companies included plans for a pilot program that will expand coverage for the drugs to additional high-risk obese and overweight people.
The Trump administration this year has also negotiated several unrelated deals with drug companies to lower the cost of their products for the wider population.
Pharmaceutical companies, meanwhile, have sued over the Medicare drug negotiations enabled by the 2022 Inflation Reduction Act and remain opposed to them.
“Whether it is the IRA or MFN, government price setting for medicines is the wrong policy for America,” Alex Schriver, senior vice president of public affairs at the Pharmaceutical Research and Manufacturers of America, or PhRMA, said in a statement. “These flawed policies also threaten future medical innovation by siphoning $300 billion from biopharmaceutical research, undermining the American economy and our ability to compete globally.”
Next year, Medicare will negotiate prices for another round of 15 drugs, including physician-administered drugs for the first time.
The Dictatorship
Trump says he’ll release MRI results
WASHINGTON (AP) — Donald Trump’ s doctor says the president had MRI imaging on his heart and abdomen in October as part of a preventative screening for men his age, according to a memo from the physician released by the White House on Monday.
Sean Barbabella said in a statement that Trump’s physical exam included “advanced imaging” that is “standard for an executive physical” in Trump’s age group. Barbabella concluded that the cardiovascular and abdominal imaging was “perfectly normal.”
“The purpose of this imaging is preventative: to identify issues early, confirm overall health, and ensure he maintains long-term vitality and function,” the doctor wrote.
The White House released Barbabella’s memo after Trump on Sunday said he would release the results of the scan. He and the White House have said the scan was “part of his routine physical examination” but had declined until Monday to detail why Trump had an MRI during his physical in October at Walter Reed National Military Medical Center or on what part of his body.
“I think that’s quite a bit of detail,” White House press secretary Karoline Leavitt said Monday when announcing the memo’s release.
The Republican president said Sunday during an exchange with reporters as he traveled back to Washington from Florida that the results of the MRI were “perfect.”
“If you want to have it released, I’ll release it,” Trump said.
Trump added Sunday that he has “no idea” on what part of his body he got the MRI.
“It was just an MRI,” he said. “What part of the body? It wasn’t the brain because I took a cognitive test and I aced it.”
Doctors typically order an MRI to help with diagnosing symptoms or to monitor an ongoing health problem. So-called “preventive” cardiac and abdominal MRIs are not part of routine screening recommendations. What Trump’s doctor called an “executive physical” generally refers to adding extra, non-routine tests including MRIs to pricey and lengthy exams, not covered by insurance, that are marketed to wealthy people.
The Dictatorship
Trump commutes prison sentence for private equity executive
HALLANDALE BEACH, Fla. (AP) — President Donald Trump has commuted the prison sentence of former investment manager David Gentile, who was convicted of defrauding investors — the latest in a series of clemency actions Trump has taken in white-collar criminal cases.
Gentile had reported to prison on Nov. 14, just days before Trump commuted his sentence, according to a White House official who requested anonymity to provide details of the clemency action. Gentile had been the CEO and co-founder of GPB Capital, which had raised $1.6 billion in capital to acquire companies in the auto, retail, health care and housing sectors.
He had been sentenced to seven years in prison after an August 2024 conviction for his role in what the Justice Department at the time described as a scheme to defraud more than 10,000 investors by misrepresenting the performance of three private equity funds.
But the White House official said GPB Capital had disclosed to investors in 2015 that their capital might go to pay dividends to other investors, which the White House said undercut claims that the company had engaged in a “Ponzi” scheme in which new investments are used to reimburse previous investors.
The government has agreed to no restitution in the criminal case, though various civil cases are handling repayments and damages to investors.
The Dictatorship
Lawmakers voice support for congressional reviews of Trump’s military strikes on boats
WASHINGTON (AP) — Lawmakers from both parties said Sunday they support congressional reviews of U.S. military strikes against vessels suspected of smuggling drugs in the Caribbean Sea and eastern Pacific Ocean, citing a published report that Defense Secretary Pete Hegseth issued a verbal order for all crew members to be killed as part of a Sept. 2 attack.
The lawmakers said they did not know whether last week’s Washington Post report was true, and some Republicans were skeptical, but they said attacking survivors of an initial missile strike poses serious legal concerns.
“This rises to the level of a war crime if it’s true,” said Sen. Tim Kaine, D-Va.
Rep. Mike Turner, R-Ohio, when asked about a follow-up strike aimed at people no longer able to fight, said Congress does not have information that happened. He noted that leaders of the Armed Services Committee in both the House and Senate have opened investigations.
“Obviously, if that occurred, that would be very serious and I agree that that would be an illegal act,” Turner said.
Meanwhile, President Donald Trump on Sunday evening while flying back to Washington from Florida, where he celebrated Thanksgiving, confirmed that he had recently spoken with Venezuelan President Nicolás Maduro.
The U.S. administration says the strikes in the Caribbean are aimed at cartels, some of which it claims are controlled by Maduro. Trump also is weighing whether to carry out strikes on the Venezuelan mainland.
Trump declined to comment on details of the call, which was first reported by The New York Times.
“I wouldn’t say it went well or badly,” Trump told reporters aboard Air Force One, when asked about the call.
The Venezuelan communications ministry did not immediately respond to a request for comment about the call with Trump.
Turner said there are concerns in Congress about the attacks on vessels that the Trump administration says are transporting drugs, but the allegation regarding the Sept. 2 attack “is completely outside anything that has been discussed with Congress and there is an ongoing investigation.”
The comments from lawmakers during news show appearances come as the administration escalates a campaign to combat drug trafficking into the U.S. On Saturday, Trump said the airspace “above and surrounding” Venezuela should be considered as “closed in its entirety,” an assertion that raised more questions about the U.S. pressure on Maduro. Maduro’s government accused Trump of making a ”colonial threat” and seeking to undermine the South American country’s sovereignty.
After the Post’s report, Hegseth said Friday on X that “fake news is delivering more fabricated, inflammatory, and derogatory reporting to discredit our incredible warriors fighting to protect the homeland.”
“Our current operations in the Caribbean are lawful under both U.S. and international law, with all actions in compliance with the law of armed conflict—and approved by the best military and civilian lawyers, up and down the chain of command,” Hegseth wrote.
Trump said on Sunday the administration “will look into” the matter but added, “I wouldn’t have wanted that — not a second strike.” The president also defended Hegseth.
“Pete said he did not order the death of those two men,” Trump said. He added, “And I believe him.”
Republican Sen. Roger Wicker of Mississippi, chairman of the Senate Armed Services Committee, and its top Democrat, Rhode Island Sen. Jack Reed, said in a joint statement late Friday that the committee “will be conducting vigorous oversight to determine the facts related to these circumstances.”
That was followed Saturday with the chairman of the House Armed Services Committee, Republican Rep. Mike Rogers of Alabama, and the ranking Democratic member, Washington Rep. Adam Smith, issuing a joint statement saying the panel was committed to “providing rigorous oversight of the Department of Defense’s military operations in the Caribbean.”
“We take seriously the reports of follow-on strikes on boats alleged to be ferrying narcotics in the SOUTHCOM region and are taking bipartisan action to gather a full accounting of the operation in question,” Rogers and Smith said, referring to U.S. Southern Command.
Rep. Don Bacon, R-Neb., asked about the Sept. 2 attack, said Hegseth deserves a chance to present his side.
“We should get to the truth. I don’t think he would be foolish enough to make this decision to say, kill everybody, kill the survivors because that’s a clear violation of the law of war,” Bacon said. “So, I’m very suspicious that he would’ve done something like that because it would go against common sense.”
Kaine and Turner appeared on CBS’ “Face the Nation,” and Bacon was on ABC’s “This Week.”
-
Uncategorized1 year ago
Bob Good to step down as Freedom Caucus chair this week
-
Politics9 months agoFormer ‘Squad’ members launching ‘Bowman and Bush’ YouTube show
-
The Dictatorship10 months agoPete Hegseth’s tenure at the Pentagon goes from bad to worse
-
Politics9 months agoBlue Light News’s Editorial Director Ryan Hutchins speaks at Blue Light News’s 2025 Governors Summit
-
The Dictatorship10 months agoLuigi Mangione acknowledges public support in first official statement since arrest
-
The Josh Fourrier Show1 year agoDOOMSDAY: Trump won, now what?
-
Politics8 months agoDemocrat challenging Joni Ernst: I want to ‘tear down’ party, ‘build it back up’
-
Politics9 months agoFormer Kentucky AG Daniel Cameron launches Senate bid






